With ongoing clinical trials on the combination of ICI and tocilizumab for malignant melanoma, urothelial carcinoma, and non-small cell lung cancer (NCT04940299), further studies are needed to clarify the optimal timing, dosing, and integration of IL-6 blockade in ICI-based regimens. Here, IL6 is linked to non-small cell lung carcinoma.